JENNIFER STODDEN: Open Payments
NPI 1730185604 · ONAWA, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$716 in 43 payments from 19 companies in 2025. Trend: 2023 $405 · 2024 $420 · 2025 $716
Food & beverage: $716
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $246 |
| Lundbeck LLC | 5 | $90 |
| AstraZeneca Pharmaceuticals LP | 3 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Octapharma USA, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Seqirus USA Inc | 1 | $22 |
| Boston Scientific Corporation | 1 | $20 |
Products named: REXULTI, VRAYLAR, QULIPTA, AUSTEDO XR, UBRELVY, INSPIRE, TEFLARO, OCTAGAM IMMUNE GLOBULIN (HUMAN).
Industry payments across IA — which companies pay providers there.
